Biogen, Inc. has been no stranger to the biopharma spotlight during the past few years, but behind the scrutiny of the company’s Alzheimer’s drug approvals and its need to return to revenue growth, head of development Priya Singhal spearheaded a thoughtful approach to restructuring the pipeline that began before Christopher Viehbacher became CEO and instituted commercial and R&D cost-cutting aimed at resetting Biogen’s trajectory.
Biogen’s Singhal Offers A Look Into Company's Pipeline Review
Explains How Company Validated Its Assets, Reduced Portfolio Risk
Priya Singhal, head of development, spoke with Scrip about the company’s R&D restructuring, readouts coming from the culled pipeline and how Biogen is thinking about adding to it in the future.
More from Business
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Scrip
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.